

Solenic Medical selected by RESI judges as one of the top pitches during the Innovator's Pitch Challenge in Boston.

Boston, MA (September 27, 2024) -

Solenic Medical Inc. was selected as one of the highest scoring pitches at the Redefining Early Stage Investments (RESI) Boston event presented by Life Science Nation. 56 innovative companies were divided into 14 sessions, each with four unique startups organized by sector or technology. A panel of experienced judges selected top scoring pitches, like Solenic's, based on their high-quality pitches, ability to address difficult topics, and clear communication of their value offer.

Start-ups, early-stage investors, and strategic channel partners are brought together by the Redefining Early Stage Investments (**RESI**) conference series. By helping fundraising startups identify partners who complement their technology and development stage, RESI makes the most of their efforts. RESI connects start-ups with ten types of worldwide investors across the silos of pharmaceuticals, devices, diagnostics, and digital health (4 Ds). It is unique in that it is cross-border and cross-domain. RESI provides services for early-stage companies looking for series A and B finance as well as grants, angel, and seed capital for start-ups. For locating resources and promoting innovation in early-stage life science and healthcare, RESI is a special and effective instrument.



About Solenic Medical Inc.

Solenic Medical, Inc. is a medical device company developing an innovative non-invasive treatment for infected metallic implants in the body. Using technology invented at the University of Texas Southwestern, Solenic is leveraging the unique properties of alternating magnetic fields (AMF) generated by external coils to reduce, and possibly eradicate, the biofilm on the surface of metallic implants. This non-invasive, non-contact treatment addresses a major complication frequently associated with various surgeries such as knee and hip replacements, and orthopedic trauma cases requiring plates, rods, and/or nails. The technology is particularly important and timely given the rise in the aging population, longer life expectancy, and the rapid increase in the number of orthopedic procedures being performed every year. Solenic's AMF technology has been designated a Breakthrough Device by the U.S. FDA. It has the potential to completely replace the costly and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Solenic Medical, Inc. is a VIC Technology Venture Development™ portfolio company.